These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 17105583

  • 1. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
    Yu ML, Dai CY, Lee LP, Hou NJ, Hsieh MY, Huang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.
    Liver Int; 2006 Dec; 26(10):1187-95. PubMed ID: 17105583
    [Abstract] [Full Text] [Related]

  • 2. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
    Sakugawa H, Nakasone H, Nakayoshi T, Kawakami Y, Yamashiro T, Maeshiro T, Kinjo F, Saito A, Yakabi S.
    Hepatogastroenterology; 2003 Dec; 50(49):165-9. PubMed ID: 12630015
    [Abstract] [Full Text] [Related]

  • 3. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
    Bargiggia S, Thorburn D, Anderloni A, Ardizzone S, Giorgi A, Bianchi Porro G, Parente F.
    Aliment Pharmacol Ther; 2005 Aug 01; 22(3):209-15. PubMed ID: 16091058
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
    Alberti AB, Belli LS, Airoldi A, de Carlis L, Rondinara G, Minola E, Vangeli M, Cernuschi A, D'Amico M, Forti D, Pinzello G.
    Liver Transpl; 2001 Oct 01; 7(10):870-6. PubMed ID: 11679985
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study.
    Andreone P, Cursaro C, Gramenzi A, Fiorino S, Di Giammarino L, Miniero R, D'Errico A, Grigioni WF, Gasbarrini G, Bernardi M.
    Ital J Gastroenterol Hepatol; 1999 Nov 01; 31(8):688-94. PubMed ID: 10730561
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Chronic hepatitis C in patients with persistently normal alanine transaminase levels.
    Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, Rodríguez-Torres M, Lardelli P, Blotner S, Zeuzem S.
    Clin Gastroenterol Hepatol; 2006 May 01; 4(5):645-52. PubMed ID: 16630770
    [Abstract] [Full Text] [Related]

  • 10. A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors.
    Yu ML, Dai CY, Chen SC, Lee LP, Huang JF, Lin ZY, Hsieh MY, Wang LY, Chuang WL, Chang WY.
    Antiviral Res; 2004 Jul 01; 63(1):25-32. PubMed ID: 15196817
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Assessment of selected clinical factors as predictors of response to combined interferon-alpha plus ribavirin therapy among patients with chronic hepatitis C.
    Kryczka W, Zarebska-Michaluk D, Chrapek M.
    Med Sci Monit; 2003 Aug 01; 9 Suppl 3():32-5. PubMed ID: 15156609
    [Abstract] [Full Text] [Related]

  • 13. High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard alpha-interferon and ribavirin.
    Saeian K, Bajaj JS, Franco J, Knox JF, Daniel J, Peine C, McKee D, Varma RR, Ho S, Midwest Hepatitis Study Group.
    Aliment Pharmacol Ther; 2004 Nov 15; 20(10):1189-93. PubMed ID: 15569122
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
    Moriyama M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Shioda A, Kaneko M, Goto I, Tanaka N, Arakawa Y.
    Liver Int; 2005 Feb 15; 25(1):85-90. PubMed ID: 15698403
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA, Liaskos C, Rigopoulou EI, Togousidis E, Makaritsis K, Germenis A, Dalekos GN.
    Am J Gastroenterol; 2008 Mar 15; 103(3):605-14. PubMed ID: 18190648
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Efficacy of combined antiviral therapy with interferon alfa and ribavirin in chronic hepatitis C patients with extrahepatic manifestations].
    Zarebska-Michaluk D, Lebensztejn DM, Kryczka W.
    Przegl Epidemiol; 2007 Mar 15; 61(3):551-8. PubMed ID: 18069393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.